zanamivir
Commercial- Indications
- Influenza
Company intelligence / Profile preview
Biota Holdings Limited
Melbourne / Notting Hill, Victoria, Australiabiota.com.au ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Developed zanamivir—the first-in-class neuraminidase inhibitor marketed as Relenza by GlaxoSmithKline. Licensed HCV nucleoside analogues to Boehringer Ingelheim. Co-developed second-generation influenza antivirals with Daiichi Sankyo. Lead HRV compound was in clinical trials as of last reports. Received significant royalties from Relenza sales. Merged into Vaxart in late 2012.
- Therapeutic areas
- Infectious Diseases
- Modalities
- small moleculesnucleoside analoguesneuraminidase inhibitors
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
GlaxoSmithKline – commercialization of zanamivir/RelenzaBoehringer Ingelheim – licensing/development agreement on HCV programDaiichi Sankyo – co-development of laninamivir and other second-generation influenza antivirals
Beyond the preview
Go deeper on Biota Holdings Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biota Holdings Limited.